Ultomiris Rapidly Eases Symptoms of Generalized MG in Phase 3 Trial

Ultomiris Rapidly Eases Symptoms of Generalized MG in Phase 3 Trial

314730

Ultomiris Rapidly Eases Symptoms of Generalized MG in Phase 3 Trial

Treatment with Ultomiris (ravulizumab-cwvz), a complement-blocking therapy, quickly eased symptom severity in adults with generalized myasthenia gravis (gMG), according to data from a Phase 3 trial. Findings were shared at the Myasthenia Gravis Foundation of America (MGFA) Scientific Sessions 2021 in the presentation, “Efficacy and safety of ravulizumab, a long-acting terminal complement inhibitor, in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: Results from the phase 3 CHAMPION MG study” (abstract No. 29). “These data…

You must be logged in to read/download the full post.